The CXCR2 antagonist SB225002 stalls CML cells in the G2/M phase, inhibiting proliferation while reducing mTOR, c-Myc, and BCR-ABL expression. The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.